Bevacizumab is approved for the treatment of colorectal cancer, breast cancer, non-small cell lung cancer and renal cell cancer. Before embracing this expensive agent for many other indications, it remains critical to be aware of the evidence upon which oncologists base their day-to-day clinical practice. In this review, we address the results of clinical studies upon which bevacizumab's current use is based and discuss some future perspectives.

Bevacizumab, Cancer, Treatment, adjuvant therapy, alpha interferon, article, bevacizumab, breast cancer, cancer adjuvant therapy, cancer combination chemotherapy, capecitabine, carboplatin, cetuximab, cisplatin, colorectal cancer, cyclophosphamide, digestive system perforation, docetaxel, fluorouracil, folinic acid, gemcitabine, human, interferon, irinotecan, kidney cancer, lung cancer, lung hemorrhage, lung non small cell cancer, ovary cancer, oxaliplatin, paclitaxel, panitumumab, priority journal, sorafenib, sunitinib, trastuzumab,
European Journal of Cancer
Erasmus MC: University Medical Center Rotterdam

Eskens, F.A.L.M, & Sleijfer, S. (2008). The use of bevacizumab in colorectal, lung, breast, renal and ovarian cancer: Where does it fit?. European Journal of Cancer, 44(16), 2350–2356. doi:10.1016/j.ejca.2008.07.042